General Information of Drug (ID: DMW1NKO)

Drug Name
X-82 Drug Info
Indication
Disease Entry ICD 11 Status REF
Age-related macular degeneration 9B75.0 Phase 2 [1]
Macular degeneration 9B78.3 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
59215954
TTD Drug ID
DMW1NKO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [5]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [4]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [4]
KH-902 DM8VO16 Diabetic macular edema 9B71.02 Phase 3 [6]
ABP 938 DM00ACQ Neovascular age-related macular degeneration 9B78.3Z Phase 3 [7]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
BAY-57-9352 DMVA5NS Gastric adenocarcinoma 2B72 Phase 2 [9]
Vorolanib DMIM1U9 Non-small-cell lung cancer 2C25 Phase 2 [10]
BFH-772 DMVUX1C Psoriasis vulgaris EA90 Phase 2 [11]
ASP-8477 DMBZQS7 Neuropathic pain 8E43.0 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [13]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [14]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [5]
CT-102 DMB8PF3 Diabetic foot ulcer BD54 Approved [15]
Trapidil DMY67U8 Acute coronary syndrome BA41 Phase 4 [16]
TKI258 DMYLT67 Renal cell carcinoma 2C90 Phase 3 [13]
BAY-57-9352 DMVA5NS Gastric adenocarcinoma 2B72 Phase 2 [13]
Vorolanib DMIM1U9 Non-small-cell lung cancer 2C25 Phase 2 [10]
PMID25623274-Compound-WO2014132220C2 DMXEZWP Pulmonary arterial hypertension BB01.0 Patented [17]
PMID25623274-Compound-WO2014132220C1 DMA2IMQ Pulmonary arterial hypertension BB01.0 Patented [17]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [18]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [19]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [20]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [21]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [22]
OCV-101 DMT9QI2 Pancreatic cancer 2C10 Phase 2 [23]
LY3012212 DMRVEHY Arteriosclerosis BD40 Phase 2 [24]
OTSGC-A24 DMN0ZQ5 Colorectal cancer 2B91.Z Phase 1/2 [25]
CEP-11981 DMYDTJ6 Solid tumour/cancer 2A00-2F9Z Phase 1 [26]
EW-A-401 DM3VC6T Peripheral vascular disease BD4Z Phase 1 [27]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Modulator [3]
Vascular endothelial growth factor receptor (VEGFR) TTVJ1D8 NOUNIPROTAC Inhibitor [4]
Vascular endothelial growth factor receptor 1 (FLT-1) TT2Q6G1 VGFR1_HUMAN Modulator [3]

References

1 ClinicalTrials.gov (NCT02348359) X-82 to Treat Age-related Macular Degeneration. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Tyrogenex.
3 National Cancer Institute Drug Dictionary (drug id 695817).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
7 Clinical pipeline report, company report or official report of Amgen
8 National Cancer Institute Drug Dictionary (drug id 452042).
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
11 CA patent application no. 841416, Method of selecting therapeutic indications.
12 ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
13 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
14 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
15 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
16 Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
17 Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.
18 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
20 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
21 Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
22 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
23 Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104.
24 Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.
25 J Clin Oncol 33, 2015 (suppl 3; abstr 65).
26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189).
27 DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007